FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer. . J Nucl Med 2022;63:13N.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2022;63:13N.
PMID: 35487569